Cure My Disease

Don't miss your cure!

 Log in / Sign up

Broccoli extract studied for autism – but study never started

NCT ID NCT07047976

Symptom relief Sponsor: Jian-Jun Ou Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study planned to test whether sulforaphane, a compound found in broccoli, could improve social skills and behavior in people with autism spectrum disorder (ASD). Researchers aimed to enroll 50 people with ASD aged 12–34 and 30 healthy volunteers, giving the ASD group sulforaphane tablets daily for 8 weeks. However, the study was withdrawn before any participants were enrolled, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sulforaphane (a compound from broccoli and other cruciferous vegetables)
What this could lead to
If it had worked, this could have pointed toward a dietary supplement to help ease social and behavioral symptoms in autism.
What could go wrong
The study was withdrawn before enrolling anyone, so no data were collected. Even if it had run, it was small (50 participants) and short (8 weeks), making it too early to draw firm conclusions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Started

Sep 2024

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 34 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for ASD Group: 1. Age between 12-34 years. 2. Diagnosis of Autism Spectrum Disorder (ASD) as per the DSM-V criteria. 3. Diagnosis of ASD according to the Autism Diagnostic Interview-Revised (ADI-R). 4. Diagnosis of ASD based on the Autism Diagnostic Observation Schedule (ADOS). Exclusion Criteria for ASD Group: a. Presence of severe physical illnesses or conditions, such as: 1. Congenital heart disease 2. Thyroid disorders 3. Liver or kidney dysfunction 4. Visual or hearing impairments b. Severe neurological diseases with a clear family history or potential risk factors, such as: a)Traumatic brain injury b) Encephalitis c) Epilepsy d) High fever seizures e) Birth trauma f） Abnormal EEG c. Known or suspected genetic disorders, such as: 1. Down syndrome 2. Fragile X syndrome d. Diagnosis of other developmental disorders, such as: a) Isolated intellectual disability b) Isolated language development disorder c) Selective mutism e. Diagnosis of other major psychiatric disorders, such as: 1. Schizophrenia 2. Bipolar disorder f. Currently taking other psychiatric or neurological medications. Inclusion Criteria for Healthy Control Group: 1. Age between 12-34 years. 2. No diagnosis of any mental disorders. Exclusion Criteria for Healthy Control Group:Exclusion criteria are the same as those for the ASD group.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autism spectrum disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autism spectrum disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autism spectrum disorder Sulforaphane

Contacts and locations

Locations

  • Department of Psychiatry, Xiangya Second Hospital, Central South University

    Changsha, Hunan, 410000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.